Loading...
Market
Will Merck receive FDA approval for CN201 therapy by December 31, 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA official website or press release
Story
Merck to Acquire CN201 Therapy from Curon for $700M, Plus Earnouts
Aug 9, 2024, 10:55 AM
Merck has announced its acquisition of the investigational B-cell depletion therapy CN201 from Curon Biopharmaceutical. The deal includes an upfront payment of $700 million in cash, with potential earnouts of up to $600 million. This acquisition is part of Merck's strategy to expand its pipeline, particularly in the areas of B-cell malignancies and autoimmune diseases. The therapy, described as a novel investigational bispecific antibody, is expected to enhance Merck's offerings in these therapeutic areas.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
More than $1 billion • 25%
